{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:07:41Z","timestamp":1789038461354,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Existing meta-analytic evidence on bipolar mania treatment has revealed that augmentation therapy (AUG) with antipsychotics and mood stabilizers is more effective than monotherapy. However, the speed of the onset of treatment effects and subsequent changes in risk\/benefit are unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched the Cochrane CENTRAL, MEDLINE, and EMBASE databases until January 2021. Our primary outcomes were response and tolerability. We set 3 time points: 1, 3, and 6 weeks after randomization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventeen studies compared AUG therapy and MS monotherapy (comparison 1), and 8 studies compared AUG therapy and antipsychotics monotherapy (comparison 2). In comparison 1, AUG therapy resulted in significantly more responses than monotherapy, with an odds ratio of 1.45 (95% confidence interval [CI]: 1.17 to 1.80) at 3 weeks and 1.59 (95% CI: 1.28 to 1.99) at 6 weeks. Significant improvement was observed in the first week with a standardized mean difference of \u22120.25 (95% CI: \u22120.38 to \u22120.12). In comparison 2, AUG therapy was significantly more effective than monotherapy, with an odds ratio of 1.73 (95% CI: 1.25 to 2.40) at 3 weeks and 1.74 (95% CI: 1.11 to 2.73) at 6 weeks. Significant improvement was observed in the first week with an standardized mean difference of \u22120.23 (95% CI: \u22120.39 to \u22120.07). Regarding tolerability, there was no significant difference between AUG therapy and monotherapy at 3 and 6 weeks in both comparisons.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Early AUG therapy should be considered, as it has shown efficacy from weeks 1 to 6, although attention to side effects is necessary for acute mania treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyac050","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T15:59:55Z","timestamp":1659801595000},"page":"839-852","source":"Crossref","is-referenced-by-count":19,"title":["Mood Stabilizers and Antipsychotics for Acute Mania: Systematic Review and Meta-Analysis of Augmentation Therapy vs Monotherapy From the Perspective of Time to the Onset of Treatment Effects"],"prefix":"10.1093","volume":"25","author":[{"given":"Aran","family":"Tajika","sequence":"first","affiliation":[{"name":"Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Fukuoka University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-3096","authenticated-orcid":false,"given":"Jun-ichi","family":"Iga","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Koshikawa","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kansai Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kansai Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine and School of Public Health , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kyorin University School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7856-3952","authenticated-orcid":false,"given":"Tadafumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kansai Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Saitama Medical University , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-7272","authenticated-orcid":false,"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"2022102508011250800_CIT0001","volume-title":"Diagnostic and Statistical Manual of Mental Disorders"},{"key":"2022102508011250800_CIT0002","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jad.2010.09.011","article-title":"Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study","volume":"129","author":"Berwaerts","year":"2011","journal-title":"J Affect Disord"},{"key":"2022102508011250800_CIT0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.1979.01780030093009","article-title":"Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study","volume":"36","author":"Biederman","year":"1979","journal-title":"Arch Gen Psychiatry"},{"key":"2022102508011250800_CIT0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40345-014-0014-9","article-title":"Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study","volume":"2","author":"Bourin","year":"2014","journal-title":"Int J Bipolar Disord"},{"key":"2022102508011250800_CIT0005","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00004714-199912000-00003","article-title":"Acute mania: haloperidol dose and augmentation with lithium or lorazepam","volume":"19","author":"Chou","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"2022102508011250800_CIT0006","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"2022102508011250800_CIT0008","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","article-title":"A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania","volume":"41","author":"Delbello","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2022102508011250800_CIT0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"2022102508011250800_CIT0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/NDT.S100846","article-title":"Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review","volume":"12","author":"Fornaro","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2022102508011250800_CIT0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"2022102508011250800_CIT0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"2022102508011250800_CIT0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0165-0327(80)90029-4","article-title":"A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania","volume":"2","author":"Garfinkel","year":"1980","journal-title":"J Affect Disord"},{"key":"2022102508011250800_CIT0014","doi-asserted-by":"crossref","first-page":"e05","DOI":"10.4088\/JCP.0208e05","article-title":"Interventions for acute mood episodes in patients with bipolar disorder","volume":"69","author":"Garlow","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2022102508011250800_CIT0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2022102508011250800_CIT0016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15622970902823202","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania","volume":"10","author":"Grunze","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"2022102508011250800_CIT0017","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.08m04895yel","article-title":"Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study","volume":"70","author":"Houston","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"2022102508011250800_CIT0018","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/pcn.12060","article-title":"Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012","volume":"67","author":"Kanba","year":"2013","journal-title":"Psychiatry Clin Neurosci"},{"key":"2022102508011250800_CIT0019","doi-asserted-by":"crossref","first-page":"g5673","DOI":"10.1136\/bmj.g5673","article-title":"Assessment and management of bipolar disorder: summary of updated NICE guidance","volume":"349","author":"Kendall","year":"2014","journal-title":"BMJ"},{"key":"2022102508011250800_CIT0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bdi.13053","article-title":"Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"23","author":"Kishi","year":"2021","journal-title":"Bipolar Disord"},{"key":"2022102508011250800_CIT0021","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2022102508011250800_CIT0022","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41386-019-0440-6","article-title":"Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2022102508011250800_CIT0023","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-9338(13)77147-5","article-title":"A 12-week, randomized, placebo-controlled study evaluating the efficacy and safety of aripiprazole in combination with lithium\/valproate in partially responsive bipolar mania","volume":"28","author":"Loze","year":"2013","journal-title":"European Psychiatry"},{"key":"2022102508011250800_CIT0024","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/bdi.13036","article-title":"The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary","volume":"22","author":"Malhi","year":"2020","journal-title":"Bipolar Disord"},{"key":"2022102508011250800_CIT0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0278-5846(89)90009-2","article-title":"Double blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol","volume":"13","author":"M\u00f6ller","year":"1989","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2022102508011250800_CIT0026","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5539\/gjhs.v6n6p163","article-title":"Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial","volume":"6","author":"Moosavi","year":"2014","journal-title":"Glob J Health Sci"},{"key":"2022102508011250800_CIT0027","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00004714-200004000-00012","article-title":"Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group","volume":"20","author":"M\u00fcller-Oerlinghausen","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"2022102508011250800_CIT0028","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40263-014-0197-8","article-title":"Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination\/augmentation therapy versus monotherapy","volume":"28","author":"Ogawa","year":"2014","journal-title":"CNS Drugs"},{"key":"2022102508011250800_CIT0029","first-page":"9","article-title":"Treatment of acute mania","volume":"26","author":"Oral","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"key":"2022102508011250800_CIT0030","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1176\/appi.ajp.2020.19091000","article-title":"20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings","volume":"177","author":"Rhee","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2022102508011250800_CIT0031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-5618.2004.00115.x","article-title":"Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study","volume":"6","author":"Sachs","year":"2004","journal-title":"Bipolar Disord"},{"key":"2022102508011250800_CIT0032","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety","volume":"159","author":"Sachs","year":"2002","journal-title":"Am J Psychiatry"},{"key":"2022102508011250800_CIT0033","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.4088\/JCP.11m07388","article-title":"Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Sachs","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2022102508011250800_CIT0034","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.4088\/JCP.11m07389","article-title":"Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection","volume":"73","author":"Sachs","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2022102508011250800_CIT0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pnpbp.2018.03.014","article-title":"Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial","volume":"84","author":"Sahraian","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2022102508011250800_CIT0036","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bdi.12959","article-title":"Pharmacological management of bipolar disorder: Japanese expert consensus","volume":"22","author":"Sakurai","year":"2020","journal-title":"Bipolar Disord"},{"key":"2022102508011250800_CIT0037","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","article-title":"Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Scherk","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"2022102508011250800_CIT0038","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0447.2006.00912.x","article-title":"Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs monotherapy","volume":"115","author":"Smith","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"2022102508011250800_CIT0039","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"2022102508011250800_CIT0041","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31823f872f","article-title":"Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension","volume":"32","author":"Szegedi","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"2022102508011250800_CIT0042","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ijnp\/pyx002","article-title":"Treatment guidelines in bipolar disorders and the importance of proper clinical trial design","volume":"20","author":"Tohen","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"2022102508011250800_CIT0043","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.107.041301","article-title":"Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes","volume":"192","author":"Tohen","year":"2008","journal-title":"Br J Psychiatry"},{"key":"2022102508011250800_CIT0044","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"2022102508011250800_CIT0045","first-page":"31","article-title":"Management of acute mania","volume":"60","author":"Tohen","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"2022102508011250800_CIT0046","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1176\/appi.ajp.2008.07101560","article-title":"Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate\/lithium monotherapy: a placebo-controlled study","volume":"165","author":"Vieta","year":"2008","journal-title":"Am J Psychiatry"},{"key":"2022102508011250800_CIT0047","volume-title":"International Statistical Classification of Disease and Related Health Problems"},{"key":"2022102508011250800_CIT0048","first-page":"1265","article-title":"Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group","volume":"11","author":"Xu","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2022102508011250800_CIT0049","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"2022102508011250800_CIT0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial","volume":"182","author":"Yatham","year":"2003","journal-title":"Br J Psychiatry"},{"key":"2022102508011250800_CIT0051","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/YIC.0b013e328080ca57","article-title":"A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania","volume":"22","author":"Yatham","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"2022102508011250800_CIT0052","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/npp.2010.192","article-title":"Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials","volume":"36","author":"Yildiz","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"2022102508011250800_CIT0053","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyac050\/45893098\/pyac050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/25\/10\/839\/46616893\/pyac050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/25\/10\/839\/46616893\/pyac050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T08:03:48Z","timestamp":1666685028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/25\/10\/839\/6657737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,8,6]]},"published-print":{"date-parts":[[2022,10,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyac050","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,8,6]]}}}